研究揭示了EcDNA在癌症增长中的作用;新药BBI-2779显示治疗前景良好。 Research reveals ecDNA's role in cancer growth; new drug BBI-2779 shows promise in treatment.

在一份科学期刊上发表的最近的研究报告探讨了外色素DNA及其在癌症发展和治疗抗药性方面的作用。 Recent research published in a scientific journal explores extrachromosomal DNA (ecDNA) and its role in cancer progression and treatment resistance. EcDNA有助于肿瘤的生长,并可能妨碍治疗的有效性。 EcDNA contributes to tumor growth and can hinder treatment effectiveness. 一种新的口服药物BBI-2779显示,在缩缩肿瘤和防止小鼠抗药性方面有希望。 A new oral drug, BBI-2779, shows promise in shrinking tumors and preventing resistance in mice. 此外,CHK1抑制剂可能会有选择地将肿瘤细胞作为EcDNA的目标,为乳癌、脑癌和肺癌等具有攻击性的癌症提供潜在的新治疗选择。 Additionally, CHK1 inhibitors may selectively target tumor cells with ecDNA, offering potential new treatment options for aggressive cancers like breast, brain, and lung cancer.